Brent Saunders (Richard Drew, AP Images)
June 24, 2020 08:54 AM EDTUpdated 10:04 AM
People
Bioregnum
Opinion

Day one: The dis­rup­tor-in-chief at Bridge­Bio in­vites Brent Saun­ders on­to the board

Now that Al­ler­gan has been swept up in­to Ab­b­Vie fol­low­ing their $63 bil­lion buy­out, it’s time for ex-CEO Brent Saun­ders to kick­start the …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Ad­vanz Phar­ma faces re­vo­ca­tion of Eu­ro­pean au­tho­riza­tion for liv­er dis­ease drug Ocali­va

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

A service from the Financial Times